Journal of Reproduction & Infertility

Journal of Reproduction & Infertility

Sociodemographic Factors Associated with Pap Test Adherence and Cervical Dysplasia in Surgically Sterilized Women

Authors
1 Department of Obstetrics and Gynecology, General Division, Baylor College of Medicine, Houston,, Texas, USA
2 Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas, USA; Division of Epidemiology, Human Genetics, and Environmental Sciences, University of Texas School of Public Health, Houston, Texas, USA
3 Department of Obstetrics and Gynecology School of Medicine, Philadelphia, Pennsylvania, USA; Center for Women's Health Research Drexel University, School of Medicine, Philadelphia, Pennsylvania, USA
4 Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas, USA; Department of Pediatrics, Division of Hematology-Oncology, Baylor College of Medicine, Houston, Texas, USA
5 Department of Obstetrics and Gynecology, General Division, Baylor College of Medicine, Houston,, Texas, USA; Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, Baylor College of Medicine, Houston, Texas,
Abstract
Background: Routine dysplasia screening decreases the rates of cervical cancer. Since many women seek gynecological care to secure contraception, it was hypothesized that sterilized women will be less likely to undergo routine cervical cancer screening. Prior studies tried to evaluate this relationship, but results were conflicting. The study sought to further explore the sociodemographic and behavioral risk factors that might predispose sterilized women to be screening non-adherent and more likely to have cervical dysplasia. Methods: Secondary analysis of women (n=1688) enrolled in a cross-sectional study in North America and divided into screening (n=925) and diagnostic (n=763) groups was performed. Information about sociodemographic and behavioral risk factors, surgical sterilization and date of last Pap test were obtained from questionnaires. Cervical histology was obtained from pathology records. Univariable analyses identified differences in risk factors between groups. Multivariable logistic regression models were constructed to evaluate Pap adherence and cervical dysplasia. Results: Sterilized women were 39% more likely to be screening non-adherent (p≤0.05) especially if divorced, separated or widowed (OR=1.62), Hispanic (OR=1.57) and with a higher number of vaginal births (OR=2.00). Education was an effect measure modifier, significantly associated with non-adherence (OR=1.60). The association between sterilization and non-adherence remained significant when adjusted for confounders (AOR=1.47). Sterilization was associated with an 80% increased odds of cervical dysplasia in women over 40. Conclusion: Sterilized women with certain sociodemographic factors are more likely to be non-adherent with Pap screening and more prone to dysplasia. These findings may assist practitioners in counseling at-risk patients.
Keywords

  1. DiSaia P, Creasmen W. Clinical gynecologic oncology. 7th ed. Philadelphia, PA: Elsevier; 2007.
  2. Mathew A, George PS. Trends in incidence and mortality rates of squamous cell carcinoma and adenocarcinoma of cervix--worldwide. Asian Pac J Cancer Prev. 2009;10(4):645-50.
  3. American Cancer Society. What are the key statistics about cervical cancer? [Internet]. Atlanta, GA: American Cancer Society; 2014 [updated 2014; cited 2014 Feb 6]. Available from: http://www.cancer.org/cancer/cervicalcancer/detailedguide/cervical-cancer-key-statistics
  4. Waggoner SE. Cervical cancer. Lancet. 2003;361(9376):2217-25.
  5. American Cancer Society. Cancer Prevention & Early Detection Facts & Figures 2012 [Internet]. Atlanta, GA: American Cancer Society; 2012 [updated 2014; cited 2014 Feb 6]. Available from: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-033423.pdf.
  6. Martin CK, Richardson LC, Berkman ND, Kuo TM, Yuen AN, Benard VB. Impact of the 2002 American society for Colposcopy and Cervical Pathology guidelines on cervical cancer diagnosis in a geographically diverse population of commercially insured women, 1999-2004. J Low Genit Tract Dis. 2011;15(1):25-32.
  7. Stanley M. Pathology and epidemiology of HPV infection in females. Gynecol Oncol. 2010;117(2 Suppl):S5-10.
  8. Speroff L, Darney P. A clinical guide for contraception. 4th ed. Philadelphia, PA: Lippincott, William & Wilkins; 2005.
  9. Eggleston KS, Coker AL, Williams M, Tortolero-Luna G, Martin JB, Tortolero SR. Cervical cancer survival by socioeconomic status, race/ethnicity, and place of residence in Texas, 1995-2001. J Womens Health (Larchmt). 2006;15(8):941-51.
  10. Cohen MM, Roos NP. Cervical cytology screening after tubal ligation. Am J Prev Med. 1986;2(4):220-5.
  11. Kjaer SK, Mellemkjaer L, Brinton LA, Johansen C, Gridley G, Olsen JH. Tubal sterilization and risk of ovarian, endometrial and cervical cancer. A Danish population-based follow-up study of more than 65 000 sterilized women. Int J Epidemiol. 2004;33(3):596-602.
  12. Li HQ, Thomas DB, Jin SK, Wu F. Tubal sterilization and use of an IUD and risk of cervical cancer. J Womens Health Gend Based Med. 2000;9(3):303-10.
  13. Winkler HA, Anderson PS, Fields AL, Runowicz CD, DeVictoria C, Goldberg GL. Compliance with Papanicolaou smear screening following tubal ligation in women with cervical cancer. J Womens Health. 1999;8(1):103-7.
  14. Mathews CA, Stoner JA, Wentzensen N, Moxley KM, Tenney ME, Tuller ER, et al. Tubal ligation frequency in Oklahoma women with cervical cancer. Gynecol Oncol. 2012;127(2):278-82.
  15. Pham B, Rhodes H, Milbourne A, Adler-Storthz K, Follen M, Scheurer ME. Epidemiologic differentiation of diagnostic and screening populations for the assessment of cervical dysplasia using optical technologies. Gend Med. 2012;9(1 Suppl):S36-47.
  16. Pruitt SL, Parker PA, Peterson SK, Le T, Follen M, Basen-Engquist K. Knowledge of cervical dysplasia and human papillomavirus among women seen in a colposcopy clinic. Gynecol Oncol. 2005;99(3 Suppl 1):S236-44.
  17. Scheurer ME, Tortolero-Luna G, Guillaud M, Follen M, Chen Z, Dillon LM, et al. Correlation of human papillomavirus type 16 and human papillomavirus type 18 e7 messenger RNA levels with degree of cervical dysplasia. Cancer Epidemiol Biomarkers Prev. 2005;14(8):1948-52.
  18. Coker AL, Desimone CP, Eggleston KS, White AL, Williams M. Ethnic disparities in cervical cancer survival among Texas women. J Womens Health (Larchmt). 2009;18(10):1577-83.
  19. Garner EI. Cervical cancer: disparities in screening, treatment, and survival. Cancer Epidemiol Biomarkers Prev. 2003;12(3):242s-247s.
  20. Ibfelt E, Kjær SK, Johansen C, Hogdall C, Steding-Jessen M, Frederiksen K, et al. Socioeconomic position and stage of cervical cancer in Danish women diagnosed 2005 to 2009. Cancer Epidemiol Biomarkers Prev. 2012 May;21(5):835-42.
  21. MacLaughlan SD, Lachance JA, Gjelsvik A. Correlation between smoking status and cervical cancer screening: a cross-sectional study. J Low Genit Tract Dis. 2011;15(2):114-9.
  22. Nelson W, Moser RP, Gaffey A, Waldron W. Adherence to cervical cancer screening guidelines for U.S. women aged 25-64: data from the 2005 Health Information National Trends Survey (HINTS). J Womens Health (Larchmt). 2009;18(11):1759-68.
  23. Russo E, Kupek E, Zanine RM. Vaginal delivery and low immunity are strongly associated with high-grade cervical intraepithelial neoplasia in a high-risk population. J Low Genit Tract Dis. 2011;15(3):195-9.
  24. Smith AM, Heywood W, Ryall R, Shelley JM, Pitts MK, Richters J, et al. Association between sexual behavior and cervical cancer screening. J Womens Health (Larchmt). 2011;20(7):1091-6.
  25. U.S. Preventive Services Task Force. Screening for cervical cancer: recommendations and rationale. Am J Nurs. 2003;103(11):101-2, 105-6, 108-9.
  26. International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, Berrington de González A, Colin D, Franceschi S, et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet. 2007;370(9599):1609-21.
  27. ACOG Committee on Practice Bulletins Gynecology. ACOG Practice Bulletin no. 109: Cervical cytology screening. Obstet Gynecol. 2009;114(6):1409-20.
  28. ACOG committee opinion. Recommendations on frequency of Pap test screening. Number 152--March 1995. Committee on Gynecologic Practice. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet. 1995;49(2):210-1.
  29. Smith RA, Brooks D, Cokkinides V, Saslow D, Brawley OW. Cancer screening in the United States, 2013: a review of current American Cancer Society guidelines, current issues in cancer screening, and new guidance on cervical cancer screening and lung cancer screening. CA Cancer J Clin. 2013;63(2):88-105.
  30. Roland KB, Soman A, Benard VB, Saraiya M. Human papillomavirus and Papanicolaou tests screening interval recommendations in the United States. Am J Obstet Gynecol. 2011;205(5):447.e1-8.
  31. Saraiya M, Berkowitz Z, Yabroff KR, Wideroff L, Kobrin S, Benard V. Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians recommending?. Arch Intern Med. 2010;170(11):977-85.
  32. Sirovich BE, Welch HG. The frequency of Pap smear screening in the United States. J Gen Intern Med. 2004;19(3):243-50.
  33. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol. 2007;197(4):340-5.
  34. Canadian Task Force on Preventive Health Care, Pollock S, Dunfield L, Shane A, Kerner J, Bryant H, et al. Recommendations on screening for cervical cancer. CMAJ. 2013;185(1):35-45.